Merck & Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair
Portfolio Pulse from Vandana Singh
Merck & Co is accused of underplaying the mental health risks of its asthma and allergy drug, Singulair. Lawsuits allege that Merck knew the drug could significantly impact the brain and downplayed the potential for psychiatric problems. In 2020, the FDA mandated a 'black box' warning for Singulair.
June 26, 2023 | 6:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Merck & Co faces lawsuits accusing the company of underplaying mental health risks from its asthma and allergy drug, Singulair. The FDA mandated a 'black box' warning for the drug in 2020.
The lawsuits against Merck & Co could lead to financial penalties and reputational damage for the company. The FDA-mandated 'black box' warning may also negatively impact the sales of Singulair, affecting Merck's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100